(CERS) Cerus - Overview
Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 549m USD | Total Return: 116.7% in 12m
Avg Turnover: 5.50M
Qual. Beats: 1
Rev. Trend: 99.0%
Qual. Beats: 1
Warnings
Interest Coverage Ratio -2.1 is critical
Altman Z'' -15.00 < 1.0 - financial distress zone
Tailwinds
Rs Leader, Idiosyncratic Leader, Tailwind
Cerus Corporation (NASDAQ: CERS) is a biomedical firm specializing in pathogen reduction technology for the global blood transfusion market. Its core product, the INTERCEPT Blood System, utilizes proprietary biological replication control to inactivate viruses, bacteria, and parasites in donated platelets, plasma, and red blood cells.
The company operates within the Health Care Supplies sector, where business models often rely on a razor-and-blade strategy, placing hardware like the INTERCEPT Illuminator to drive recurring revenue through specialized disposable kits. This sector is characterized by high regulatory barriers and rigorous FDA and CE Mark approval processes, which serve as significant moats for established incumbents.
Cerus maintains a diversified geographic footprint, utilizing a mix of direct sales forces and international distributors to supply hospitals and blood centers across North America, Europe, and the Middle East. Investors may find it useful to check ValueRay for more detailed financial analysis. The firms expansion into pathogen-reduced cryoprecipitated fibrinogen complex targets the critical care segment for treating massive hemorrhage and fibrinogen deficiency.
- FDA approval and market adoption of INTERCEPT red blood cell system
- Expansion of pathogen reduction technology into global blood center operations
- Government funding and contract renewals for biomedical defense applications
- High manufacturing costs impacting transition to sustained GAAP profitability
- Regulatory shifts in blood safety standards across European and Asian markets
| Net Income: -9.55m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.01 > 0.02 and ΔFCF/TA -3.79 > 1.0 |
| NWC/Revenue: 30.50% < 20% (prev 49.60%; Δ -19.09% < -1%) |
| CFO/TA 0.01 > 3% & CFO 2.63m > Net Income -9.55m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.63 > 1.5 & < 3 |
| Outstanding Shares: last quarter (194.1m) vs 12m ago 3.78% < -2% |
| Gross Margin: 54.31% > 18% (prev 0.56%; Δ 5.37k% > 0.5%) |
| Asset Turnover: 103.7% > 50% (prev 89.54%; Δ 14.16% > 0%) |
| Interest Coverage Ratio: -2.07 > 6 (EBITDA TTM -14.5m / Interest Expense TTM 8.11m) |
| A: 0.30 (Total Current Assets 175.3m - Total Current Liabilities 107.4m) / Total Assets 222.9m |
| B: -4.86 (Retained Earnings -1.08b / Total Assets 222.9m) |
| C: -0.08 (EBIT TTM -16.7m / Avg Total Assets 214.8m) |
| D: -7.00 (Book Value of Equity -1.08b / Total Liabilities 154.6m) |
| Altman-Z'' = -21.71 = D |
| DSRI: 0.92 (Receivables 29.3m/26.3m, Revenue 222.8m/185.1m) |
| GMI: 1.03 (GM 54.31% / 56.00%) |
| AQI: 0.92 (AQ_t 0.13 / AQ_t-1 0.14) |
| SGI: 1.20 (Revenue 222.8m / 185.1m) |
| TATA: -0.05 (NI -9.55m - CFO 2.63m) / TA 222.9m) |
| Beneish M = -3.02 (Cap -4..+1) = AA |
As of May 27, 2026, the stock is trading at USD 2.73 with a total of 1,039,954 shares traded.
Over the past week, the price has changed by +12.35%,
over one month by +37.88%,
over three months by +5.00% and
over the past year by +116.67%.
Cerus has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy CERS.
- StrongBuy: 4
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 4.7 | 71.1% |
P/S = 2.5352
P/B = 8.1271
Revenue TTM = 222.8m USD
EBIT TTM = -16.7m USD
EBITDA TTM = -14.5m USD
Long Term Debt = 32.4m USD (from longTermDebt, last quarter)
Short Term Debt = 55.5m USD (from shortTermDebt, last quarter)
Debt = 109.9m USD (from shortLongTermDebtTotal, last quarter) + Leases 12.5m
Net Debt = 29.5m USD (calculated: Debt 109.9m - CCE 80.4m)
Enterprise Value = 578.5m USD (549.0m + Debt 109.9m - CCE 80.4m)
Interest Coverage Ratio = -2.07 (Ebit TTM -16.7m / Interest Expense TTM 8.11m)
EV/FCF = -474.9x (Enterprise Value 578.5m / FCF TTM -1.22m)
FCF Yield = -0.21% (FCF TTM -1.22m / Enterprise Value 578.5m)
FCF Margin = -0.55% (FCF TTM -1.22m / Revenue TTM 222.8m)
Net Margin = -4.29% (Net Income TTM -9.55m / Revenue TTM 222.8m)
Gross Margin = 54.31% ((Revenue TTM 222.8m - Cost of Revenue TTM 101.8m) / Revenue TTM)
Gross Margin QoQ = 56.98% (prev 51.51%)
Tobins Q-Ratio = 2.60 (Enterprise Value 578.5m / Total Assets 222.9m)
Interest Expense / Debt = 7.38% (Interest Expense 8.11m / Debt 109.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -13.2m (EBIT -16.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.63 (Total Current Assets 175.3m / Total Current Liabilities 107.4m)
Debt / Equity = 1.63 (Debt 109.9m / totalStockholderEquity, last quarter 67.6m)
Debt / EBITDA = -2.04 (negative EBITDA) (Net Debt 29.5m / EBITDA -14.5m)
Debt / FCF = -24.19 (negative FCF - burning cash) (Net Debt 29.5m / FCF TTM -1.22m)
Total Stockholder Equity = 62.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -4.45% (Net Income -9.55m / Total Assets 222.9m)
RoE = -0.83% (Net Income TTM -9.55m / Total Stockholder Equity 1.14b)
RoCE = -1.42% (EBIT -16.7m / Capital Employed (Equity 1.14b + L.T.Debt 32.4m))
RoIC = -14.60% (negative operating profit) (NOPAT -13.2m / Invested Capital 90.6m)
WACC = 10.04% (E(549.0m)/V(658.9m) * Re(10.88%) + D(109.9m)/V(658.9m) * Rd(7.38%) * (1-Tc(0.21)))
Discount Rate = 10.88% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.11 | Cagr: 3.11%
[DCF] Fair Price = unknown (Cash Flow -1.22m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.72 | # QB: 1
Revenue Correlation: 99.03 | Revenue CAGR: 14.26% | SUE: 1.82 | # QB: 1
EPS current Quarter (2026-06-30): EPS=-0.01 | Chg30d=N/A | Revisions=-20% | Analysts=2
EPS next Quarter (2026-09-30): EPS=-0.01 | Chg30d=N/A | Revisions=-20% | Analysts=2
EPS current Year (2026-12-31): EPS=-0.03 | Chg30d=+50.00% | Revisions=-33% | GrowthEPS=+62.5% | GrowthRev=+15.5%
[Analyst] Revisions Ratio: -33%